Needham & Company LLC Issues Pessimistic Forecast for Merit Medical Systems (NASDAQ:MMSI) Stock Price

Merit Medical Systems (NASDAQ:MMSI) had its price target lowered by equities research analysts at Needham & Company LLC from $108.00 to $101.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s price objective suggests a potential upside of 22.53% from the company’s previous close.

A number of other research firms have also commented on MMSI. BTIG Research assumed coverage on Merit Medical Systems in a report on Friday, February 6th. They issued a “buy” rating and a $107.00 target price for the company. Barrington Research reiterated an “outperform” rating and issued a $106.00 price objective on shares of Merit Medical Systems in a report on Friday, November 14th. Piper Sandler lowered their target price on shares of Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 18th. Wells Fargo & Company reduced their price target on shares of Merit Medical Systems from $103.00 to $95.00 and set an “overweight” rating for the company in a research note on Friday, November 14th. Finally, Robert W. Baird set a $108.00 price objective on shares of Merit Medical Systems in a research report on Tuesday, December 16th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $104.89.

Merit Medical Systems Stock Up 1.0%

Shares of Merit Medical Systems stock opened at $82.43 on Wednesday. The company has a 50-day simple moving average of $84.08 and a two-hundred day simple moving average of $84.98. The stock has a market capitalization of $4.89 billion, a PE ratio of 42.27, a price-to-earnings-growth ratio of 2.22 and a beta of 0.61. Merit Medical Systems has a 52-week low of $77.62 and a 52-week high of $107.27. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.86 and a current ratio of 4.28.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.08. Merit Medical Systems had a net margin of 8.02% and a return on equity of 14.27%. The firm had revenue of $393.94 million for the quarter, compared to analysts’ expectations of $390.77 million. During the same quarter in the prior year, the company posted $0.93 earnings per share. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. On average, analysts anticipate that Merit Medical Systems will post 3.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL purchased a new stake in shares of Merit Medical Systems in the 3rd quarter worth $2,913,050,000. State Street Corp raised its stake in shares of Merit Medical Systems by 1.5% in the fourth quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock worth $196,645,000 after buying an additional 32,459 shares during the period. Fuller & Thaler Asset Management Inc. lifted its position in shares of Merit Medical Systems by 12.7% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after buying an additional 234,682 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Merit Medical Systems by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,437,397 shares of the medical instruments supplier’s stock valued at $134,384,000 after acquiring an additional 39,620 shares during the period. Finally, Maverick Capital Ltd. increased its holdings in Merit Medical Systems by 8.4% in the 2nd quarter. Maverick Capital Ltd. now owns 1,379,408 shares of the medical instruments supplier’s stock worth $128,947,000 after acquiring an additional 106,897 shares in the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Key Stories Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 results beat — EPS of $1.04 vs. consensus $0.96 and revenue of $393.9M vs. $390.8M; revenue grew ~10.9% year-over-year, with reported net margin ~8% and ROE ~14%. These metrics point to demand recovery and margin improvement. Merit Medical Systems Earnings Report
• Positive Sentiment: Upside FY2026 guidance — management raised full‑year EPS to $4.010–4.150 versus the prior consensus (~$3.73), implying stronger margin expansion and earnings growth for 2026. This is the main catalyst supporting the stock’s move higher. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst/press coverage detailing quarter and metrics — third‑party writeups (Zacks) confirm the beat and walk through key metric comparisons to estimates and prior year results; useful for due diligence but largely reiterative of company numbers. Merit Medical (MMSI) Q4 Earnings and Revenues Top Estimates
• Neutral Sentiment: Local/summary coverage — CT Post and other outlets published earnings snapshots summarizing the results and call; useful for quick read but unlikely to move the stock beyond the company-provided figures. Merit Medical: Q4 Earnings Snapshot
• Negative Sentiment: Price target trimmed — Needham’s Michael Matson kept a Buy rating but lowered the price target to $101, which signals more conservative near-term upside expectations despite the favorable results. That trimmed PT could cap immediate analyst-driven upside. Merit Medical Systems: Strong Q4 Beat, Upbeat 2026 Outlook…

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.